US 11,866,500 B2
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
Xing Sun, Jiangsu (CN); Guoqing Cao, Jiangsu (CN); Changyong Yang, Jiangsu (CN); Lianshan Zhang, Jiangsu (CN); and Yong Guo, Jiangsu (CN)
Assigned to Suzhou Suncadia Biopharmaceuticals Co., Ltd., Suzhou (CN); Jiangsu Hengrui Medicine Co., Ltd., Lianyungang (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Minhang District (CN)
Filed by Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu (CN); Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., Shanghai (CN)
Filed on Nov. 12, 2021, as Appl. No. 17/454,634.
Application 17/454,634 is a continuation of application No. 16/339,819, granted, now 11,208,484, previously published as PCT/CN2017/105410, filed on Oct. 9, 2017.
Claims priority of application No. 201610884688.3 (CN), filed on Oct. 10, 2016.
Prior Publication US 2022/0119528 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/444 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 9/0053 (2013.01); A61K 31/444 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)] 17 Claims
 
1. A method for treating cancer in a subject in need thereof, the method comprising administering to the subject, an anti-PD-1 antibody and apatinib or a pharmaceutically acceptable salt thereof, wherein the anti-PD-1 antibody comprises:
an antibody light chain variable region comprising LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and
an antibody heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 having the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively,
wherein the apatinib or the pharmaceutically acceptable salt thereof is administered orally at a dose from 125 mg to 375 mg.